Inhibition of nitric oxide synthase--potential for a novel class of therapeutic agent?
The free-radical gas nitric oxide (NO) plays an important role in a wide and diverse range of physiological processes. As progress is made in understanding the biological function of NO, there is growing interest in the possibility that inhibitors of NO synthase (NOS) may be of clinical use in the therapy of certain disease states. The search for novel and clinically relevant inhibitors of this enzyme represents a truly multidisciplinary approach to drug screening and will no doubt benefit from the application of recombinant DNA (rDNA) technology.
Ogden
J E
JE
Biomedical Sciences Division, King's College, London, UK.
Moore
P K
PK
D000594:Amino Acid Oxidoreductases / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000737:chemistry; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007527:Isoenzymes / Q000737:chemistry; D019331:NG-Nitroarginine Methyl Ester; D009569:Nitric Oxide / Q000502:physiology; D019001:Nitric Oxide Synthase; D011994:Recombinant Proteins / Q000096:biosynthesis; D019323:omega-N-Methylarginine
D007527:Isoenzymes; D011994:Recombinant Proteins; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D001120:Arginine; D019001:Nitric Oxide Synthase; D000594:Amino Acid Oxidoreductases; D019331:NG-Nitroarginine Methyl Ester